Ondansetron Hydrochloride Tablets

This product is a potent, highly selective 5-HT3 receptor antagonist with a strong antiemetic effect. Chemotherapy drugs and radiotherapy can cause the small intestine to release 5-HT, which activates the afferent branch of the vagus nerve through the 5-HT3 receptor and triggers the vomiting reflex. This product can block the triggering of this reflex. The stimulation of the afferent branch of the vagus nerve can also cause the release of 5-HT in the Postrema area at the bottom of the fourth ventricle, thereby enhancing it through the central mechanism. This product is effective for nausea and vomiting caused by chemotherapy and radiotherapy. Therefore, this product exerts its antiemetic effect by antagonizing the 5-HT receptors of neurons located in the peripheral and central nervous systems. The mechanism of action of postoperative nausea and vomiting is unclear, but it may be induced by a common pathway similar to nausea and vomiting caused by cytotoxic drugs. This product can also inhibit nausea induced by opioids, and its

Ondansetron hydrochloride.

It is a white or off-white tablet.

Antiemetic. Indicated for: 1. Nausea and vomiting caused by cytotoxic chemotherapy and radiotherapy. 2. Prevention and treatment of postoperative nausea and vomiting.

1 For vomiting caused by highly emetic chemotherapy drugs: inject 8 mg of ondansetron injection intravenously 15 minutes before chemotherapy, 4 hours and 8 hours after chemotherapy, and take 8 mg of ondansetron tablets orally every 8 to 12 hours after stopping chemotherapy for 5 consecutive days. 2 For vomiting caused by chemotherapy drugs that are not too emetic: inject 8 mg of ondansetron injection intravenously 15 minutes before chemotherapy, and take 8 mg of ondansetron tablets orally every 8 to 12 hours thereafter for 5 consecutive days. 3 For vomiting caused by radiotherapy: the first dose must be taken orally as a tablet of 8 mg 1 to 2 hours before radiotherapy, and then take 8 mg orally every 8 hours. The course of treatment depends on the course of radiotherapy. 4 For prevention of nausea and vomiting after surgery

There may be headache, abdominal discomfort, constipation, dry mouth, rash, occasional bronchial asthma or allergic reactions, and transient asymptomatic increase in transaminase. The above reactions are mild and do not require special treatment. Some patients have epileptic seizures. There are also rare reports of chest pain, arrhythmia, hypotension, and bradycardia.

Those who are allergic to this product. Those with gastrointestinal obstruction.

Precautions for children: This experiment has not been conducted and there are no reliable references. Precautions for pregnancy and lactation: The safety of this product during human pregnancy has not been determined. Animal experiments have not shown direct or indirect harm to the embryonic, fetal, pregnancy, perinatal and postpartum periods. However, since animal studies cannot fully predict human reactions, it is not recommended for use during pregnancy, especially in the first three months of pregnancy. Experiments have shown that this product can be secreted in the milk of lactating animals, so breastfeeding should be suspended when taking this product. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

1. There is no evidence that this product will induce or inhibit the metabolism of other drugs taken at the same time. Special studies have shown that this product has no interaction with alcohol, temazepam, furosemide, tramadol and propofol. 2. Patients with poor metabolism of separteine and isoquine have no effect on the elimination half-life of this product. After repeated administration to such patients, the drug exposure level is no different from that of normal humans, so the dosage and frequency of medication do not need to be changed. 3. Combination with dexamethasone can enhance the antiemetic effect.

Store below 30℃ away from light. Valid for three years.

4mg (based on C18H19N3O)

36 months.

PKU HealthCare Corp., Ltd.

• Founded in:

  1993-05-18

• Address:

  No. 21, Fangzheng Avenue, Shuitu Town, Beibei District, Chongqing

• Tax NO.:

  91500000450533779H

• Registered Funds:

  595.987425 yuan

• Website:

  Log in to view

• Email:

  Log in to view